Scientists from Singapore discovered a novel low-cost method of testing for cancers. The test sequences heated clinical samples to isolate cancer-specific signatures found in a patient’s blood.
The first blood test to diagnose inflammation of the heart muscle (myocarditis) could be in use in as little as a year, following the discovery of a molecular signal in the blood.
During the Covid-19 pandemic, the use of these single-use diagnostics, or point-of-care tests has exploded. This is having major environmental consequences, experts point out.
New tests can identify over 50 types of cancer and boost detection of traditionally elusive cancers from tumour DNA in blood, researchers showed at the ESMO congress in September. These multi-cancer early detection (MCED) tests in development can spot common cancer signals and predict where the signal comes from in the body, results from a prospective investigation suggest.
Speed or accuracy? As far as Covid-19 tests go, this was the choice you had to make. In the future, this dilemma could be a thing of the past.
The Pluslife Mini Dock System is a Next-Generation POC molecular diagnostic tool that can be used in different application scenarios, which aims to help the decentralization of MDx in diagnosing facilities.
With the rise of syndrome-style infections, co-infections and the current antimicrobial resistance challenges, the need for multiplexed diagnostics is now more important than ever.
The coronavirus pandemic is a huge challenge for global public health and welfare. Decentralized, affordable POC MDx platforms would allow more effective control of SARS-CoV-2 and other infections.
What if a test analysing cervical cells from a gynaecological swab could be used to detect four different female cancers at an early stage and also predict cancer risk over a healthy woman's lifetime? Researchers at the EUTOPS Institute in Innsbruck, Austria, are developing tests to do just that for breast, ovarian, cervical, and endometrial cancer detection.
Antibiotic prescribing in primary care could be monitored using health insurance data. And reduced with a simple test.
Driving the healthcare industry towards digital transformation was the main direction of Automa+ 2022. The Congress gathered leaders from hospitals and healthcare providers, pharmaceutical companies, governmental bodies and institutions as well as medical device manufacturers, service providers and start-ups in Zurich, Switzerland on September, 26-27, 2022.
How can rapid antigen tests be adjusted to reliably detect future variants of SARS-CoV-2? A research team funded by the National Institutes of Health is currently working on finding an answer.
Two-dimensional (2D) cultured cell lines and animal models have been the principal research tools for the past decade, but have several shortcomings. Three-dimensional cell cultures, or organoids, show great promise here.
Urine screening tests using only immunoassays are the most common procedures used to identify drug abuse. They are inexpensive, automated, and produce rapid results. But they may generate false-positive or false-negative results, which vary based on the drug, drug class, and the assay used. Hair toxicology analysis is another form of drug testing which, unlike urine tests, enable analysis of drug…
The new test measures the level of neutralizing antibodies in a blood sample and could help people decide what protections they should take against infection.
The prototype device combines eRapid and SHERLOCK technologies into a single, postcard-sized system that can simultaneously detect the presence of both SARS-CoV-2 RNA and antibodies in a patient’s saliva.
Researchers have developed a new Covid-19 test distribution method that uses drones to quickly deliver at-home diagnostic tests to individuals who suspect they have Covid-19.
The European Society for Emergency Medicine (EUSEM) held their annual congress on October 27th to 31st, 2021 in the city of Lisbon, to promote education, training and research in European acute care.
Handheld, instrument-free test delivers lab-quality molecular results – 97.9% accuracy – in about 15 minutes, right at the point of care.
Researchers have developed a novel way to fabricate diagnostic devices using paper-based microfluidics that can be rapidly prototyped and scaled for manufacturing.
Sofia 2 C. difficile FIA is a new solution to provide reliable and rapid test results with high clinical relevance before empiric therapy decisions are implemented.
A new handheld device has been developed to painlessly identify skin cancers using millimeter-wave imaging. This could slash the rate of unnecessary biopsies.
The in vitro diagnostic regulation (IVDR) aims to make tests safer, more reliable, and sustainable. Unfortunately, it is also widely regarded a bureaucratic nightmare. At the ECCMID Day on Diagnostics, an expert proposed a more constructive approach.
Accurate home testing could be used for a wider range of illnesses, as new research shows the capability of smartphone-powered tests for Dengue Fever.
The COVID-19 testing device can detect coronavirus infection in as little as 30 seconds as sensitively and accurately as a PCR test.
